Abstract
Disease-modifying anti-rheumatic drugs (DMARDs) are typically used for the therapy of rheumatoid arthritis (RA), but most have some nephrotoxicity. In several clinical studies, etanercept had fewer adverse effects on renal function than other DMARDs. We report the case of a 64-year-old woman with RA and renal insufficiency on hemodialysis treated using etanercept therapy. This case suggests that etanercept therapy might be effective in the short term for such patients.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Stokes DG, Kremer JM. Potential of tumor necrosis factor neutralization strategies in rheumatologic disorders other than rheumatoid arthritis. Semin Arthritis Rheum. 2003;33:1–18.
Lee H, Kimko HC, Rogge M, Wang D, Nestorov I, Peck CC. Population pharmacokinetic and pharmacodynamic modeling of etanercept using logistic regression analysis. Clin Pharmacol Ther. 2003;73:348–65.
Don BR, Spin G, Nestorov I, Hutmacher M, Rose A, Kaysen GA. The pharmacokinetics of etanercept in patients with end-stage renal disease on haemodialysis. J Pharm Pharmacol. 2005;57:1407–13.
Nakamura M, Sakemi T, Nagasawa K. Severe pancytopenia caused by a single administration of low dose methotrexate in a patient undergoing hemodialysis. J Rheumatol. 1999;26:1424–5.
Akiyama Y, Fujimaki T, Sakurai Y. Pharmacokinetics of salazosulfapyridine in a hemodialysis patient (in Japanese). Ryumachi. 2003;43:569–76.
Hamada K. The safety of actarit (mover) in hemodialysis patients with rheumatoid arthritis (in Japanese). Prog Med. 1997;17:1652–7.
Kaizu K, Komine N, Uriu K, Ikeda M, Hashimoto O, Eto S. Bucillamine may be an effective anti-rheumatic drug in patients with end-stage renal disease—a case report (in Japanese). J Jpn Soc Dial Ther. 1994;27:1505–10.
Matthey F, Perrett D, Greenwood RN, Baker LRI. The use of d-penicillamine in patients with rheumatoid arthritis undergoing hemodialysis. Clin Nephrol. 1986;25:268–71.
Saisho K, Kurosawa O, Fukanoki T, Hanafusa A, Tajima N. Long-term use of mizoribine in rheumatoid arthritis patients on hemodialysis. Mod Rheumatol. 2001;11:132–5.
Beaman JM, Hackett LP, Luxton G, Illett KF. Effect of hemodialysis on leflunomide plasma concentrations. Ann Pharmacother. 2002;36:75–7.
Gruber SA, Hewitt JM, Sorenson AL. Pharmacokinetics of FK506 after intravenous and oral administration in patients awaiting renal transplantation. J Clin Pharmacol. 1994;34:859–64.
Andoh TF, Burdmann EA, Lindsley J, Houghton DC, Bennett WM. Enhancement of FK506 nephrotoxicity by sodium depletion in an experimental rat model. Transplantation. 1994;57:483–9.
Singh R, Cuchacovich R, Huang W, Espinoza LR. Infliximab treatment in a patient with rheumatoid arthritis on hemodialysis. J Rheumatol. 2002;29:636–7.
Hammoudeh M. Infliximab treatment in a patient with rheumatoid arthritis on haemodialysis. Rheumatology (Oxford). 2006;45:357–9.
Acknowledgments
The authors have no financial and personal relationship with the organization whose product or competing product plays a prominent role in this manuscript.
Author information
Authors and Affiliations
Corresponding author
About this article
Cite this article
Sugioka, Y., Inui, K. & Koike, T. Use of etanercept in a patient with rheumatoid arthritis on hemodialysis. Mod Rheumatol 18, 293–295 (2008). https://doi.org/10.1007/s10165-008-0041-4
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s10165-008-0041-4